Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Sep 25, 2024

SELL
$285.76 - $321.48 $731,259 - $822,667
-2,559 Reduced 41.71%
3,576 $1.03 Billion
Q3 2022

Sep 25, 2024

SELL
$273.83 - $305.53 $10,131 - $11,304
-37 Reduced 0.6%
6,135 $1.78 Billion
Q2 2022

Sep 25, 2024

BUY
$234.96 - $292.55 $1.45 Million - $1.81 Million
6,172 New
6,172 $1.74 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Paragon Capital Management Inc Portfolio

Follow Paragon Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Capital Management Inc with notifications on news.